Literature DB >> 10155597

Paclitaxel and docetaxel. Innovation, but at what cost?

P E Lønning.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 10155597     DOI： 10.2165/00019053-199508010-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  15 in total

Review 1.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

2.  Phase II trial of taxol in patients with metastatic renal cell carcinoma.

Authors:  A I Einzig; E Gorowski; J Sasloff; P H Wiernik
Journal:  Cancer Invest       Date:  1991       Impact factor: 2.176

3.  The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.

Authors:  T J Smith; B E Hillner
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

4.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-11       Impact factor: 79.321

5.  Direct photoaffinity labeling of tubulin with taxol.

Authors:  S Rao; S B Horwitz; I Ringel
Journal:  J Natl Cancer Inst       Date:  1992-05-20       Impact factor: 13.506

6.  Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.

Authors:  G Catimel; J Verweij; V Mattijssen; A Hanauske; M Piccart; J Wanders; H Franklin; N Le Bail; M Clavel; S B Kaye
Journal:  Ann Oncol       Date:  1994-07       Impact factor: 32.976

7.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

Authors:  E A Eisenhauer; W W ten Bokkel Huinink; K D Swenerton; L Gianni; J Myles; M E van der Burg; I Kerr; J B Vermorken; K Buser; N Colombo
Journal:  J Clin Oncol       Date:  1994-12       Impact factor: 44.544

Review 8.  Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.

Authors:  C M Spencer; D Faulds
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

Review 9.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

10.  Advanced breast cancer: use of resources and cost implications.

Authors:  M A Richards; S Braysher; W M Gregory; R D Rubens
Journal:  Br J Cancer       Date:  1993-04       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.